Surgical risk stratification in patients with cirrhosis
- PMID: 38472607
- PMCID: PMC11864775
- DOI: 10.1007/s12072-024-10644-y
Surgical risk stratification in patients with cirrhosis
Abstract
Individuals with cirrhosis experience higher morbidity and mortality rates than the general population, irrespective of the type or scope of surgery. This increased risk is attributed to adverse effects of liver disease, encompassing coagulation dysfunction, altered metabolism of anesthesia and sedatives, immunologic dysfunction, hemorrhage related to varices, malnutrition and frailty, impaired wound healing, as well as diminished portal blood flow, overall hepatic circulation, and hepatic oxygen supply during surgical procedures. Therefore, a frequent clinical dilemma is whether surgical interventions should be pursued in patients with cirrhosis. Several risk scores are widely used to aid in the decision-making process, each with specific advantages and limitations. This review aims to discuss the preoperative risk factors in patients with cirrhosis, describe and compare surgical risk assessment models used in everyday practice, provide insights into the surgical risk according to the type of surgery and present recommendations for optimizing those with cirrhosis for surgical procedures. As the primary focus is on currently available risk models, the review describes the predictive value of each model, highlighting its specific advantages and limitations. Furthermore, for models that do not account for the type of surgical procedure to be performed, the review suggests incorporating both patient-related and surgery-related risks into the decision-making process. Finally, we provide an algorithm for the preoperative assessment of patients with cirrhosis before elective surgery as well as guidance perioperative management.
Keywords: Child–Turcotte–Pugh classification; Hepatic surgery; Liver cirrhosis; MELD; Mayo risk model; Non-hepatic surgery; Surgical risk; Surgical risk assessment; VOCAL-Penn score.
© 2024. Asian Pacific Association for the Study of the Liver.
Conflict of interest statement
Ana Ostojic declares that he has no conflict of interest. Nadim Mahmud declares support from Grifols (investigator-initiated research) K. Rajender Reddy Advisory Board: Mallinckrodt, Spark Therapeutics, Novo Nordisk, Bio Vie. Grant Support (Paid to the University of Pennsylvania): Mallinckrodt, BMS, Intercept, Bio Vie, Sequana, Grifols, HCC-TARGET, NASH-TARGET, Exact Sciences, Camurus, B and D Device, DSMB: Novartis, Genkyotex, Astra Zeneca.
Figures
References
-
- Neeff H, Mariaskin D, Spangenberg HC, Hopt UT, Makowiec F. Perioperative mortality after non-hepatic general surgery in patients with liver cirrhosis: an analysis of 138 operations in the 2000s using Child and MELD scores. J Gastrointest Surg. 2011;15(1):1–11 - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
